Cancer Epigenetics Program (03)

项目概要/摘要-癌症表观遗传学研究 由Issa和Studitsky领导的癌症表观遗传学（CE）计划是Fox Chase Cancer的一个新计划 中心（气候变化框架公约）。CE计划旨在整合基础和应用研究领域， 表观遗传学它由19个主要成员组成。项目资金为每年500万美元（项目直接成本）， 包括240万美元的同行评审资金，其中100万美元来自NCI。行政长官在施政报告中， 自2012年项目启动以来，该项目取得了丰硕成果，产生了232篇出版物，其中9%来自内部， 27%是计划性的，27%是计划间的合作。 CE计划利用教师在癌症表观遗传学方面的专业知识的广度和深度， 从2012年FCCC和坦普尔大学之间的联系，以推进改善的总体目标， 通过检测、预后和治疗方面的新方法来改善癌症预后。 CE计划有四个首要主题：1）表观基因组学：破译正常和癌症表观基因组， 转化目标是发现癌症风险、预后和治疗反应的生物标志物; 2） 读者，作家和橡皮擦：研究建立，阅读，调节和延续表观遗传的蛋白质 标记，其转化目标是发现潜在的治疗靶点; 3）发育和疾病： 研究正常和异常发育中的表观遗传学，并将这些信息与已知的 癌症表观遗传学和生物学。这一主题的翻译目标是了解癌症病因， 发现为治疗目的重新编程表观基因组的方法; 4）表观遗传疗法：开发 表观遗传靶向治疗方法，并在临床前和临床研究中对其进行测试。这些主题 由多学科团队的研究人员开发，以确定和解决复杂的因素 导致癌症风险，癌症发展和癌症治疗。这一新方案是 通过招聘多名教师在所有职业阶段（初级和高级）和不同的可能性 兴趣（基本临床），并导致了一个强大的综合方案与R 01资助的基本 研究和快速积累的制药商发起的临床试验。这些合作努力创造了一个 富有成效的研究环境，促进识别新的癌症风险生物标志物， 预防性干预的分子靶点，以及成功开发和实施新的 癌症治疗的方法。CE计划成员已成功地将394名研究参与者纳入 干预性和非干预性研究，并受益于使用 CCSG支持的12个FCCC共享资源中的11个。

PROJECT SUMMARY/ABSTRACT – CANCER EPIGENETICS PROGRAM The Cancer Epigenetics (CE) Program, led by Issa and Studitsky is a new Program at Fox Chase Cancer Center (FCCC). The CE Program is designed to integrate basic and applied research in the field of epigenetics. It is comprised of 19 Primary Members. Program funding is $5M (project direct costs) annually, including $2.4M in peer-reviewed funding of which $1M is from the NCI. CE members have been highly productive since Program initiation in 2012, generating 232 publications, with 9% representing intra- programmatic and 27% representing inter-programmatic collaborations. The CE Program takes advantage of the breadth and depth of faculty expertise in cancer epigenetics arising from the 2012 affiliation between FCCC and Temple University, to advance the overall goal of improving cancer outcomes through new approaches in detection, prognosis and therapy. The CE Program has four overarching themes: 1) Epigenomics: To decipher normal and cancer epigenomes, with the translational goal of discovering biomarkers of cancer risk, prognosis and response to therapy; 2) Readers, Writers and Erasers: To study the proteins that establish, read, modulate and perpetuate epigenetic marks, with the translational goal of discovering potential targets of therapy; 3) Development and Disease: To study epigenetics in normal and abnormal development and relate this information to what is known about cancer epigenetics and biology. The translational goal of this theme is in understanding cancer etiology, and discovering ways to reprogram the epigenome for therapeutic purposes; 4) Epigenetic Therapy: To develop epigenetically-targeted therapeutic approaches and test them in pre-clinical and clinical studies. These themes are developed by investigators working in multidisciplinary teams to identify and address the complex factors that contribute to cancer risk, cancer development and cancer treatment. This new Program was made possible by the recruitment of multiple faculty members at all career stages (junior and senior) and with diverse interests (basic to clinical), and has resulted in a strongly integrated program with both R01 funded basic research and rapidly accruing investigator-initiated clinical trials. These collaborative efforts have created a productive research environment that fosters the identification of new biomarkers of cancer risk, novel molecular targets for preventive intervention, and the successful development and implementation of novel approaches to cancer therapy. CE Program members have successfully accrued 394 research participants into interventional and non-interventional studies during the last funding cycle, and have benefited from the use of 11 of the 12 CCSG-supported Shared Resources at FCCC.